NEU.AX - Neuren Pharmaceuticals Limited

ASX - ASX Delayed price. Currency in AUD
Currency in AUD

Valuation measures

Market cap (intra-day) 5179.67M
Enterprise value 3155.44M
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)362.97
Price/book (mrq)12.68
Enterprise value/revenue 3314.02
Enterprise value/EBITDA 6-14.04

Trading information

Stock price history

Beta (5Y monthly) 1.34
52-week change 344.76%
S&P500 52-week change 38.60%
52-week high 33.0400
52-week low 30.9650
50-day moving average 31.6061
200-day moving average 32.0708

Share statistics

Avg vol (3-month) 3143.09k
Avg vol (10-day) 3101.95k
Shares outstanding 5102.67M
Float 43.79M
% held by insiders 137.19%
% held by institutions 10.04%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 321 Nov 2017

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2019
Most-recent quarter (mrq)31 Dec 2019

Profitability

Profit margin 0.00%
Operating margin (ttm)-2,237.58%

Management effectiveness

Return on assets (ttm)-33.73%
Return on equity (ttm)-56.16%

Income statement

Revenue (ttm)495k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)-96.50%
Gross profit (ttm)-9.36M
EBITDA -11.07M
Net income avi to common (ttm)-10.82M
Diluted EPS (ttm)-0.1080
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)13.84M
Total cash per share (mrq)0.14
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)25.75
Book value per share (mrq)0.14

Cash flow statement

Operating cash flow (ttm)-11.72M
Levered free cash flow (ttm)-5.83M